Neurocrine Biosciences (NBIX) to Release Earnings on Wednesday

Neurocrine Biosciences (NASDAQ:NBIX) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of $1.62 per share and revenue of $629.25 million for the quarter.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $150.71 on Wednesday. The stock has a 50 day simple moving average of $135.33 and a 200 day simple moving average of $131.30. Neurocrine Biosciences has a 52-week low of $110.95 and a 52-week high of $157.98. The firm has a market capitalization of $15.26 billion, a PE ratio of 40.40 and a beta of 0.33.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now owns 15,449 shares in the company, valued at $1,951,054.21. This represents a 13.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the sale, the insider now directly owns 2,507 shares in the company, valued at $338,445. This represents a 30.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 68,694 shares of company stock worth $9,676,730 over the last ninety days. Insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Raymond James reiterated an “outperform” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a report on Thursday, October 10th. William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. Piper Sandler reaffirmed an “overweight” rating and set a $160.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Finally, Royal Bank of Canada cut their price objective on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research report on Friday, October 4th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $165.40.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.